ASP ISOTOPES INC. overview

- Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto. - The Company expects to be able to achieve a 99.75% enrichment for Ytterbium-176 and offer highly enriched Ytterbium-176 for commercial sale during 2025. - The Company anticipates now being able to proceed with the plans to construct Nickel-64, Gadolinium-160 and Lithium-6/7 Quantum Enrichment facilities. - The Company intends to continue its discussions with...

WASHINGTON, March 31, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), announced that it will release its fourth quarter and fiscal year 2024 financial results after the close of financial markets today, March 31, 2025, with a webinar to follow tomorrow, Tuesday, April 1, 2025 at 10:00 am ET, 3:00 pm UK time, 4:00 pm South African time. Participating in the webinar will be Paul Mann, Chairman and CEO of the Company. Mr. Mann will give a review of...

- Silicon-28 is an isotope that is believed to assist in enabling quantum computing and improving the performance of next generation semiconductors for artificial intelligence. - The Company expects to ship commercial product during 2Q25. - The Company has already entered into two purchase agreements with US-based customers for kilogram quantities of Silicon-28 and is in discussions with multiple other global customers for kilogram quantities. WASHINGTON, March 27, 2025 (GLOBE NEWSWIRE) -- ASP...

- The Company has commenced commercial production of enriched Carbon-14 at its first Aerodynamic Separation Process (ASP) enrichment facility. - The Company expects to ship commercial product around the middle of the year. - The Company previously entered into a multi-year, take-or-pay contract with a Canadian customer, valued at a minimum of approximately $2.4 million per annum. WASHINGTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”),...

ASP Isotopes invites institutional investors to attend the upcoming virtual event by contacting their Canaccord Genuity representative Paul Mann, Chairman and Chief Executive Officer of ASP Isotopes, will participate in a panel discussion on the future of nuclear fission. The panel will also include representatives from TerraPower and Elementl Power WASHINGTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company...

- This week the Company welcomes a group of institutional investors from around the world to its facilities located in Pretoria, South Africa for a two-day investor access event. - During the investor access event, the Company intends to show the investors the results achieved from Quantum Enrichment demonstrating an enrichment factor of up to 678, versus previous expectations of greater than 50. This compares to an enrichment factor of less than 20 for other laser-based enrichment approaches. -...

WASHINGTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman and CEO, Paul Mann. Dear Fellow Shareholder, As the year comes towards its end, I wanted to personally write to you to summarize some of the more significant...

WASHINGTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today issued the following statement in response to short seller Fuzzy Panda’s purported “report” published on November 26, 2024. Executive Chairman and Chief Executive Officer, Paul Mann, stated: “ Fuzzy Panda is known...